Geron Corporation Announces Updated NCCN Guidelines Recommending RYTELO (Imetelstat) For The Treatment Of Symptomatic Anemia In Patients With Lower-risk MDS
Portfolio Pulse from Benzinga Newsdesk
Geron Corporation announced that the updated NCCN guidelines now recommend RYTELO (Imetelstat) for the treatment of symptomatic anemia in patients with lower-risk MDS.
July 26, 2024 | 11:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Geron Corporation's RYTELO (Imetelstat) has been recommended by the updated NCCN guidelines for treating symptomatic anemia in patients with lower-risk MDS. This endorsement could lead to increased adoption and sales of RYTELO.
The NCCN guidelines are highly influential in the medical community. The recommendation of RYTELO (Imetelstat) for treating symptomatic anemia in lower-risk MDS patients is likely to boost its adoption and sales, positively impacting Geron's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100